ZA200501843B - A method of extending the dose range of vitamin D compounds - Google Patents
A method of extending the dose range of vitamin D compounds Download PDFInfo
- Publication number
- ZA200501843B ZA200501843B ZA200501843A ZA200501843A ZA200501843B ZA 200501843 B ZA200501843 B ZA 200501843B ZA 200501843 A ZA200501843 A ZA 200501843A ZA 200501843 A ZA200501843 A ZA 200501843A ZA 200501843 B ZA200501843 B ZA 200501843B
- Authority
- ZA
- South Africa
- Prior art keywords
- vitamin
- group
- inhibitors
- compound
- hydroxy
- Prior art date
Links
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims description 158
- 239000011710 vitamin D Substances 0.000 title claims description 158
- 235000019166 vitamin D Nutrition 0.000 title claims description 157
- 229940046008 vitamin d Drugs 0.000 title claims description 156
- 229930003316 Vitamin D Natural products 0.000 title claims description 155
- -1 vitamin D compounds Chemical class 0.000 title claims description 125
- 238000000034 method Methods 0.000 title description 16
- 239000003112 inhibitor Substances 0.000 claims description 189
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 97
- 229910052791 calcium Inorganic materials 0.000 claims description 97
- 239000011575 calcium Substances 0.000 claims description 97
- 210000000988 bone and bone Anatomy 0.000 claims description 87
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 239000001257 hydrogen Substances 0.000 claims description 72
- 150000003384 small molecules Chemical class 0.000 claims description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 65
- 150000002431 hydrogen Chemical class 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 42
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 42
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 42
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 36
- 102000003945 NF-kappa B Human genes 0.000 claims description 27
- 108010057466 NF-kappa B Proteins 0.000 claims description 27
- 101150014014 Traf6 gene Proteins 0.000 claims description 27
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 24
- 230000000148 hypercalcaemia Effects 0.000 claims description 24
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 24
- 125000001153 fluoro group Chemical group F* 0.000 claims description 20
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 19
- 229940062527 alendronate Drugs 0.000 claims description 19
- 229910052805 deuterium Inorganic materials 0.000 claims description 19
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 19
- 108091000080 Phosphotransferase Proteins 0.000 claims description 18
- 102000006495 integrins Human genes 0.000 claims description 18
- 108010044426 integrins Proteins 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 102000020233 phosphotransferase Human genes 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims description 17
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 17
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 229940122361 Bisphosphonate Drugs 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 102000014128 RANK Ligand Human genes 0.000 claims description 12
- 108010025832 RANK Ligand Proteins 0.000 claims description 12
- 150000004663 bisphosphonates Chemical class 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000004681 Psoriasis Diseases 0.000 claims description 11
- 108010027767 Rank-Fc Proteins 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000006386 Bone Resorption Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 230000024279 bone resorption Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000005345 deuteroalkyl group Chemical group 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 102100027584 Protein c-Fos Human genes 0.000 claims description 9
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 9
- 108091005682 Receptor kinases Proteins 0.000 claims description 9
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims description 9
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 claims description 9
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 claims description 9
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 claims description 9
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 claims description 9
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 9
- 125000001118 alkylidene group Chemical group 0.000 claims description 9
- 239000003098 androgen Substances 0.000 claims description 9
- 229940030486 androgens Drugs 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229940011871 estrogen Drugs 0.000 claims description 9
- 239000000262 estrogen Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 108091006084 receptor activators Proteins 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 9
- 238000005829 trimerization reaction Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 102100034613 Annexin A2 Human genes 0.000 claims description 2
- 108090000668 Annexin A2 Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims 15
- 102100023132 Transcription factor Jun Human genes 0.000 claims 15
- 102000004171 Cathepsin K Human genes 0.000 claims 8
- 108090000625 Cathepsin K Proteins 0.000 claims 8
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims 8
- 230000002103 transcriptional effect Effects 0.000 claims 8
- 230000001684 chronic effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 101100054466 Arabidopsis thaliana CCR3 gene Proteins 0.000 claims 1
- 101100221959 Arabidopsis thaliana CRR3 gene Proteins 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 235000005282 vitamin D3 Nutrition 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 229960005084 calcitriol Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 102000009310 vitamin D receptors Human genes 0.000 description 7
- 108050000156 vitamin D receptors Proteins 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000035987 intoxication Effects 0.000 description 6
- 231100000566 intoxication Toxicity 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 6
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 229960003783 24-homo-1,25-dihydroxyvitamin d3 Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 150000003703 vitamin D2 derivatives Chemical class 0.000 description 4
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000004765 promyelocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 2
- 235000021318 Calcifediol Nutrition 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000000125 calcaemic effect Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000001962 taste-modifying agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- PKFBWEUIKKCWEW-WEZTXPJVSA-N (1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 PKFBWEUIKKCWEW-WEZTXPJVSA-N 0.000 description 1
- WKTIGYIYJKESCJ-JJWMBMNSSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-7-hydroxy-7-methyloctan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C WKTIGYIYJKESCJ-JJWMBMNSSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 description 1
- IJNDMZIDDKVXHR-MYEQSZOMSA-N 25-Hydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C/1C(CC[C@@H](O)C\1)=C)C)[C@@H]1C[C@@](C)(O)C(=O)O1 IJNDMZIDDKVXHR-MYEQSZOMSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 102100024817 TNF receptor-associated factor 6 Human genes 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- VNWKTOKETHGBQD-YPZZEJLDSA-N carbane Chemical compound [10CH4] VNWKTOKETHGBQD-YPZZEJLDSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000030402 vitamin D-dependent rickets Diseases 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/235,244 US7259143B2 (en) | 2002-09-05 | 2002-09-05 | Method of extending the dose range of vitamin D compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200501843B true ZA200501843B (en) | 2006-05-31 |
Family
ID=31977538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501843A ZA200501843B (en) | 2002-09-05 | 2005-03-03 | A method of extending the dose range of vitamin D compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7259143B2 (fr) |
| EP (1) | EP1545549A1 (fr) |
| JP (1) | JP2006500388A (fr) |
| KR (1) | KR100835456B1 (fr) |
| CN (1) | CN1694711A (fr) |
| AU (2) | AU2003245748A1 (fr) |
| BR (1) | BR0314006A (fr) |
| CA (1) | CA2497828A1 (fr) |
| MX (1) | MXPA05002467A (fr) |
| NZ (1) | NZ539129A (fr) |
| PL (1) | PL375558A1 (fr) |
| WO (1) | WO2004022068A1 (fr) |
| ZA (1) | ZA200501843B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| US20050176685A1 (en) * | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20060189532A1 (en) * | 2005-02-14 | 2006-08-24 | Deluca Hector F | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| US7566696B2 (en) * | 2002-09-05 | 2009-07-28 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| EP1656157B1 (fr) * | 2003-08-20 | 2011-12-21 | Wisconsin Alumni Research Foundation | Composes de la 2-methylene-19-nor-vitamine d2 |
| KR20060040746A (ko) * | 2003-09-19 | 2006-05-10 | 화이자 프로덕츠 인크. | 2-알킬리덴-19-노르-비타민 ｄ 유도체와 에스트로겐효능제/길항제의 조합물을 포함하는 제약 조성물 및 방법 |
| WO2005027929A1 (fr) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un oestrogene |
| US7704980B2 (en) * | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| WO2006061683A1 (fr) * | 2004-12-09 | 2006-06-15 | Pfizer Products Inc. | Derives 2-alkylidene-19-nor de la vitamine d pour le traitement d'une osteogenese imparfaite |
| US20060194185A1 (en) * | 2005-02-10 | 2006-08-31 | David Goldberg | Information request system and method |
| US7563783B2 (en) * | 2005-02-11 | 2009-07-21 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2 |
| WO2006086608A1 (fr) * | 2005-02-11 | 2006-08-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20s-24epi)-1$g(a),25-dihydroxyvitamine-d2 |
| US20090137828A1 (en) * | 2005-08-18 | 2009-05-28 | Bioxell S.P.A. | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol |
| US20070165866A1 (en) * | 2006-01-13 | 2007-07-19 | Motorola, Inc. | Method and apparatus to facilitate conveying audio content |
| KR101959952B1 (ko) * | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US20100331286A1 (en) * | 2008-02-25 | 2010-12-30 | Ray Chow | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| TR200900880A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik bileşimler. |
| JP5814247B2 (ja) * | 2009-10-02 | 2015-11-17 | ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | １−デソキシ−２−メチレン−１９−ノル−ビタミンｄ類似体及びそれらの使用 |
| WO2012075326A2 (fr) * | 2010-12-01 | 2012-06-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Traitement de maladies inflammatoires par ciblage de la protéine adaptatrice ciks |
| US8410080B1 (en) * | 2011-10-21 | 2013-04-02 | Wisconsin Alumni Research Foundation | 2-methylene-vitamin D analogs and their uses |
| EP3331533B1 (fr) * | 2015-08-05 | 2021-09-01 | Wisconsin Alumni Research Foundation | Synthèse et activité biologique d'analogues 2-méthylène du calcitriol et de composés apparentés |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
| US5391567A (en) * | 1986-09-03 | 1995-02-21 | Macrochem Corporation | Method for treating hypercalcemia using salts of TNCA |
| US6489288B1 (en) * | 1990-03-16 | 2002-12-03 | Applied Research Systems Ars Holding | Treatment of polycystic ovarian disease |
| US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| WO2000052204A2 (fr) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Expression genique dans les tumeurs de la vessie |
| CA2396393A1 (fr) | 2000-01-04 | 2001-07-12 | The Regents Of The University Of California | Utilisation de bisphosphonates a faible dose pour inhiber la calcification cardiaque et arterielle |
| EP1416919A1 (fr) * | 2001-07-17 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate |
-
2002
- 2002-09-05 US US10/235,244 patent/US7259143B2/en not_active Expired - Fee Related
-
2003
- 2003-06-26 EP EP03739354A patent/EP1545549A1/fr not_active Withdrawn
- 2003-06-26 MX MXPA05002467A patent/MXPA05002467A/es active IP Right Grant
- 2003-06-26 AU AU2003245748A patent/AU2003245748A1/en not_active Abandoned
- 2003-06-26 JP JP2004534233A patent/JP2006500388A/ja active Pending
- 2003-06-26 WO PCT/US2003/020517 patent/WO2004022068A1/fr active Application Filing
- 2003-06-26 BR BR0314006-7A patent/BR0314006A/pt not_active IP Right Cessation
- 2003-06-26 NZ NZ539129A patent/NZ539129A/en not_active IP Right Cessation
- 2003-06-26 CA CA002497828A patent/CA2497828A1/fr not_active Abandoned
- 2003-06-26 CN CNA038248883A patent/CN1694711A/zh active Pending
- 2003-06-26 KR KR1020057003765A patent/KR100835456B1/ko not_active IP Right Cessation
- 2003-06-26 PL PL03375558A patent/PL375558A1/xx not_active Application Discontinuation
-
2005
- 2005-03-03 ZA ZA200501843A patent/ZA200501843B/en unknown
-
2009
- 2009-09-21 AU AU2009217403A patent/AU2009217403A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL375558A1 (en) | 2005-11-28 |
| KR20050057180A (ko) | 2005-06-16 |
| BR0314006A (pt) | 2005-08-09 |
| US7259143B2 (en) | 2007-08-21 |
| JP2006500388A (ja) | 2006-01-05 |
| WO2004022068A1 (fr) | 2004-03-18 |
| US20040053813A1 (en) | 2004-03-18 |
| AU2009217403A1 (en) | 2009-10-08 |
| EP1545549A1 (fr) | 2005-06-29 |
| KR100835456B1 (ko) | 2008-06-09 |
| MXPA05002467A (es) | 2005-05-27 |
| CN1694711A (zh) | 2005-11-09 |
| CA2497828A1 (fr) | 2004-03-18 |
| AU2003245748A1 (en) | 2004-03-29 |
| NZ539129A (en) | 2008-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200501843B (en) | A method of extending the dose range of vitamin D compounds | |
| US6369099B1 (en) | Method of locking 1 α-OH of vitamin D compounds in axial orientation | |
| US20080249068A1 (en) | Method of Extending the Dose Range of Vitamin D Compounds | |
| AU2004283073B2 (en) | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds | |
| EP1143949B1 (fr) | Composes de 19-nor-vitamine d3 a activite calcemique | |
| MXPA06003974A (en) | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds |